Indian Journal Of Clinical Practice
Not a member yet
747 research outputs found
Sort by
Clinical Outcomes of Slow versus Rapid Enteral Feeding Advancement in Very Low Birth Weight Neonates at a Tertiary Care Center
Get PDFIn India, every year around 3.5 million babies are born premature, accounting for almost 13% of total livebirths in the country as compared to 5% to 7% incidence in the West. Preterm is defined as babies born before 37 weeks ofpregnancy. The rapidity of feed volume increments involves controversies like faster weight gain, shorter hospital stays, therisk of necrotizing enterocolitis and vice versa. Methods: The present study was a randomized controlled trial conducted fromJune 1, 2018 to October 31, 2019. All infants in the study were randomized to slow and rapid feeding protocols by a stratifiedblock randomization sequence of 2, 4, 6 blocks. Group 1 or the slow advancement group included 64 newborns babies andGroup 2 or the rapid advancement group included 69 newborns babies. Results: The average weight gain in Group 1 was4.41 ± 0.9 g and in Group 2 it was 6.33 ± 1.3 g, the difference was statistically significant (p < 0.02). Sixty out of 64 newbornsregained birth weight within 16.87 ± 0.9 days in Group 1, while 64 out of 69 newborns regained birth weight within 13.63 ±0.9 days in Group 2. The difference was statistically significant. Increment in the mean occipitofrontal circumference perweek was 0.29 ± 0.27 cm Group 1, while in Group 2 it was 0.42 ± 0.05 cm; the difference was statistically significant. Meanaverage length increment per week was found to be 0.55 ± 0.04 cm and 0.69 ± 0.05 cm in Group 1 and Group 2, respectively,the difference was statistically significant (p < 0.005). The mean duration of hospital stay was 27.47 ± 3.33 days in Group 1while in Group 2, the duration of stay was 23.15 ± 2.22 days, the difference was statistically significant. Conclusion: Ourstudy supports enteral nutrition by rapid enteral feeding regimen in stable preterm neonates with very low birth weigh
A Rare Convergence: A Case Report on Bilateral Hypoglossal Schwannoma in a Patient with Charcot-Marie-Tooth Disease 2
Get PDFThis case presents a rare co-occurrence of Charcot-Marie-Tooth disease type 2 (CMT2) and schwannoma, shedding light on the intricate relationship between two neurogenic disorders. CMT is a hereditary sensorimotor peripheral neuropathy while schwannoma is a benign encapsulated tumor involving Schwann cells. The co-occurrence has been previously described in 2 patients in a family with CMT type 1A. Our case reports the first documented instance of the co-occurrence of bilateral hypoglossal schwannoma in CMT2
Rare Adverse Effect of a Commonly Used Drug in Chronic Kidney Disease
Get PDFChronic kidney disease (CKD) and hypertension can lead to each other. Majority of the patients with CKD have hypertension.Sympathetic overactivity has been suggested as one of the important etiologies of hypertension in CKD patients. Clonidine isused as a central sympatholytic to control hypertension in CKD patients. Drug-induced sialadenitis has been reported withmultiple drugs including antihypertensives. We report a case of clonidine-induced sialadenitis, which has been rarely seendespite the widespread use of this drug among CKD patients requiring multiple antihypertensive drugs
Person-centered Pharmaceutical Business
Get PDFPerson-centered care is a phrase, which seems omnipresent in medical discourse. Can pharmaceutical businesses andindustries be person-centric? This article explores the various facets of person-centered pharmaceutical businesses, it suggestsways of incorporating and measuring person-centricity in the business milieu, and describes best practices shared by leadingpharmaceutical houses
A Review on N-acetylcysteine: A Versatile Adjuvant in Respiratory Diseases
Get PDFN-acetylcysteine (NAC), the acetylated variant of the amino acid L-cysteine and precursor of glutathione, has severaltherapeutic uses and has been used worldwide for over 50 years. It is used as an antidote for paracetamol poisoning, fortreating neurological illnesses and substance use disorders, and as a mucolytic, antibiofilm, antioxidant, and anti-inflammatoryagent in various respiratory diseases. Therefore, NAC exhibits promising therapeutic potential and may be an effective choicefor add-on therapy. This review aims to establish the benefits of NAC beyond its mucolytic and antibiofilm actions andhighlights the utility of its antioxidant as well as anti-inflammatory activity not only in chronic respiratory diseases, such aschronic obstructive pulmonary disease (COPD) and bronchiectasis, but also in respiratory infections, such as tuberculosis,pneumonia, and coronavirus disease 2019 (COVID-19). The review will be of interest to physicians as it summarizes theadvantages of using NAC in the treatment of various respiratory disorders in their clinical practice